Immunic (IMUX)
(Delayed Data from NSDQ)
$1.83 USD
-0.12 (-6.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.84 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Immunic, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 47 | 116 | 87 | 127 | 29 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 9 | 18 | 6 | 3 |
Total Current Assets | 53 | 126 | 105 | 134 | 32 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 33 | 33 | 33 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 54 | 128 | 139 | 168 | 66 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 4 | 4 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 8 | 7 | 4 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 0 | 1 |
Total Current Liabilities | 25 | 13 | 11 | 8 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 14 | 12 | 9 | 8 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 436 | 428 | 324 | 267 | 120 |
Retained Earnings | -411 | -317 | -197 | -104 | -60 |
Other Equity | 4 | 3 | 0 | -4 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 114 | 127 | 159 | 58 |
Total Liabilities & Shareholder's Equity | 54 | 128 | 139 | 168 | 66 |
Total Common Equity | 29 | 114 | 127 | 159 | 58 |
Shares Outstanding | 45.10 | 44.30 | 26.20 | 20.70 | 10.10 |
Book Value Per Share | 0.64 | 2.57 | 4.85 | 7.67 | 5.78 |
Fiscal Year End for Immunic, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 80 | 97 | 47 | 60 | 77 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 5 | 6 | 6 | 9 |
Total Current Assets | 85 | 103 | 53 | 65 | 87 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 86 | 104 | 54 | 67 | 89 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 7 | 5 | 3 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 12 | 19 | 14 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 23 | 20 | 25 | 18 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 21 | 25 | 19 | 19 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 522 | 520 | 436 | 434 | 432 |
Retained Earnings | -462 | -440 | -411 | -389 | -367 |
Other Equity | 4 | 4 | 4 | 4 | 4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 64 | 84 | 29 | 48 | 69 |
Total Liabilities & Shareholder's Equity | 86 | 104 | 54 | 67 | 89 |
Total Common Equity | 64 | 84 | 29 | 48 | 69 |
Shares Outstanding | 90.00 | 90.00 | 45.10 | 44.60 | 44.60 |
Book Value Per Share | 0.71 | 0.93 | 0.64 | 1.09 | 1.55 |